Please ensure Javascript is enabled for purposes of website accessibility

Rockville firm gets Chinese patent for cancer technology

The SnapPath Cancer Diagnostics System generates purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. This enables the generation of PathMap functional signaling Profiles, which can predict individual solid tumor response to targeted therapies. (Photo: Business Wire)

The SnapPath Cancer Diagnostics System generates purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. This enables the generation of PathMap functional signaling Profiles, which can predict individual solid tumor response to targeted therapies. (Photo: Business Wire)

BioMarker Strategies LLC, a pharmaceutical research services firm based in Rockville, announced on Monday that it had received a Chinese patent for a cancer technology.

BioMarker’s new patent is for use of its PathMAP functional signaling profile technology for “compositions for prediction of drug sensitivity, resistance and disease progression.” That use of the technology is also patented in the United States, Europe, Australia, Canada, Japan and Singapore.

The technology can be used to assess response to targeted drugs in development for treatment of solid tumor cancers.


To purchase a reprint of this article, contact reprints@thedailyrecord.com.